Literature DB >> 17606624

Nuclear receptor corepressor is a novel regulator of phosphatidylinositol 3-kinase signaling.

Fumihiko Furuya1, Celine J Guigon, Li Zhao, Changxue Lu, John A Hanover, Sheue-yann Cheng.   

Abstract

The nuclear receptor corepressor (NCoR) regulates the activities of DNA-binding transcription factors. Recent observations of its distribution in the extranuclear compartment raised the possibility that it could have other cellular functions in addition to transcription repression. We previously showed that phosphatidylinositol 3-kinase (PI3K) signaling is aberrantly activated by a mutant thyroid hormone beta receptor (TRbetaPV, hereafter referred to as PV) via physical interaction with p85alpha, thus contributing to thyroid carcinogenesis in a mouse model of follicular thyroid carcinoma (TRbetaPV/PV mouse). Since NCoR is known to modulate the actions of TRbeta mutants in vivo and in vitro, we asked whether NCoR regulates PV-activated PI3K signaling. Remarkably, we found that NCoR physically interacted with and competed with PV for binding to the C-terminal SH2 (Src homology 2) domain of p85alpha, the regulatory subunit of PI3K. Confocal fluorescence microscopy showed that both NCoR and p85alpha were localized in the nuclear as well as in the cytoplasmic compartments. Overexpression of NCoR in thyroid tumor cells of TRbetaPV/PV mouse reduced PI3K signaling, as indicated by the decrease in the phosphorylation of its immediate downstream effector, p-AKT. Conversely, lowering cellular NCoR by siRNA knockdown in tumor cells led to overactivated p-AKT and increased cell proliferation and motility. Furthermore, NCoR protein levels were significantly lower in thyroid tumor cells than in wild-type thyrocytes, allowing more effective binding of PV to p85alpha to activate PI3K signaling and thus contributing to tumor progression. Taken together, these results indicate that NCoR, via protein-protein interaction, is a novel regulator of PI3K signaling and could serve to modulate thyroid tumor progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17606624      PMCID: PMC1952145          DOI: 10.1128/MCB.00900-07

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  24 in total

1.  Characterization of seven novel mutations of the c-erbA beta gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two "hot spot" regions of the ligand binding domain.

Authors:  R Parrilla; A J Mixson; J A McPherson; J H McClaskey; B D Weintraub
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

Review 2.  Molecular basis of resistance to thyroid hormone.

Authors:  Paul M Yen
Journal:  Trends Endocrinol Metab       Date:  2003-09       Impact factor: 12.015

3.  N-CoR controls differentiation of neural stem cells into astrocytes.

Authors:  Ola Hermanson; Kristen Jepsen; Michael G Rosenfeld
Journal:  Nature       Date:  2002-10-16       Impact factor: 49.962

4.  Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression.

Authors:  Hao Ying; Fumihiko Furuya; Li Zhao; Osamu Araki; Brian L West; John A Hanover; Mark C Willingham; Sheue-Yann Cheng
Journal:  J Clin Invest       Date:  2006-10-12       Impact factor: 14.808

5.  Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone.

Authors:  M Kaneshige; K Kaneshige; X Zhu; A Dace; L Garrett; T A Carter; R Kazlauskaite; D G Pankratz; A Wynshaw-Boris; S Refetoff; B Weintraub; M C Willingham; C Barlow; S Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

6.  Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues.

Authors:  Megumi Miyakawa; Toshio Tsushima; Hitomi Murakami; Kae Wakai; Osamu Isozaki; Kazue Takano
Journal:  Endocr J       Date:  2003-02       Impact factor: 2.349

7.  Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma.

Authors:  Hao Ying; Hideyo Suzuki; Hiroko Furumoto; Robert Walker; Paul Meltzer; Mark C Willingham; Sheue-Yann Cheng
Journal:  Carcinogenesis       Date:  2003-07-17       Impact factor: 4.944

8.  Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis.

Authors:  Hideyo Suzuki; Mark C Willingham; Sheue-Yann Cheng
Journal:  Thyroid       Date:  2002-11       Impact factor: 6.568

9.  Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein.

Authors:  Sung Hee Baek; Kenneth A Ohgi; David W Rose; Edward H Koo; Christopher K Glass; Michael G Rosenfeld
Journal:  Cell       Date:  2002-07-12       Impact factor: 41.582

10.  Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer.

Authors:  V Vasko; M Saji; E Hardy; M Kruhlak; A Larin; V Savchenko; M Miyakawa; O Isozaki; H Murakami; T Tsushima; K D Burman; C De Micco; M D Ringel
Journal:  J Med Genet       Date:  2004-03       Impact factor: 6.318

View more
  22 in total

Review 1.  Thyroid hormone receptors and cancer.

Authors:  Won Gu Kim; Sheue-yann Cheng
Journal:  Biochim Biophys Acta       Date:  2012-04-06

Review 2.  Nongenomic actions of thyroid hormone.

Authors:  Paul J Davis; Fernando Goglia; Jack L Leonard
Journal:  Nat Rev Endocrinol       Date:  2015-12-15       Impact factor: 43.330

3.  The corepressor NCoR1 antagonizes PGC-1α and estrogen-related receptor α in the regulation of skeletal muscle function and oxidative metabolism.

Authors:  Joaquín Pérez-Schindler; Serge Summermatter; Silvia Salatino; Francesco Zorzato; Markus Beer; Piotr J Balwierz; Erik van Nimwegen; Jérôme N Feige; Johan Auwerx; Christoph Handschin
Journal:  Mol Cell Biol       Date:  2012-10-01       Impact factor: 4.272

4.  Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.

Authors:  Sandra M Lopez; Alexander I Agoulnik; Manqi Zhang; Leif E Peterson; Egla Suarez; Gregory A Gandarillas; Anna Frolov; Rile Li; Kimal Rajapakshe; Christian Coarfa; Michael M Ittmann; Nancy L Weigel; Irina U Agoulnik
Journal:  Clin Cancer Res       Date:  2016-03-11       Impact factor: 12.531

Review 5.  Lessons from mouse models of thyroid cancer.

Authors:  Caroline S Kim; Xuguang Zhu
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

6.  Nuclear receptor co-repressor is required to maintain proliferation of normal intestinal epithelial cells in culture and down-modulates the expression of pigment epithelium-derived factor.

Authors:  Geneviève Doyon; Stéphanie St-Jean; Mathieu Darsigny; Claude Asselin; Francois Boudreau
Journal:  J Biol Chem       Date:  2009-07-16       Impact factor: 5.157

Review 7.  Molecular aspects of thyroid hormone actions.

Authors:  Sheue-Yann Cheng; Jack L Leonard; Paul J Davis
Journal:  Endocr Rev       Date:  2010-01-05       Impact factor: 19.871

Review 8.  Modeling thyroid cancer in the mouse.

Authors:  X-G Zhu; S-Y Cheng
Journal:  Horm Metab Res       Date:  2009-04-08       Impact factor: 2.936

9.  Novel oncogenic actions of TRbeta mutants in tumorigenesis.

Authors:  Celine J Guigon; Sheue-yann Cheng
Journal:  IUBMB Life       Date:  2009-05       Impact factor: 3.885

10.  Identification of networks of co-occurring, tumor-related DNA copy number changes using a genome-wide scoring approach.

Authors:  Christiaan Klijn; Jan Bot; David J Adams; Marcel Reinders; Lodewyk Wessels; Jos Jonkers
Journal:  PLoS Comput Biol       Date:  2010-01-01       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.